Get started
Author

Claire Dyke

Observed names: C. Dyke, C.L. Dyke, Claire Louise Dyke
ORCID: 0009-0004-3405-0177
Observed ORCID: 0009-0004-3405-0177
OpenAlex ID: A5042907776
Real-world patterns of treatment and response in metastatic renal cell carcinoma: a multicentre UK-wide review with UK Renal Oncology Collaborative (UK ROC)
2024 · R. Frazer, J.M. McGrane, et al. · ESMO Real World Data and Digital Oncology · 15
PDF
Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial
2025 · Gianmarco Leone, Francesco Orlando, et al. · JAMA Oncology · 9
Assessing the tolerability and efficacy of first-line chemotherapy in elderly patients with metastatic HER2−ve breast cancer
2019 · Thomas Wilson, Claire Dyke, et al. · ecancermedicalscience · 4
PDF
First line treatment of pancreatic metastases in metastatic renal cell carcinoma: Insights from the UK Renal Oncology Collaborative (UK ROC)—Tyrosine kinase inhibitors time to shine?
2025 · Ben Crosby, Ricky Dylan Frazer, et al. · Journal of Clinical Oncology
1711P Real-word data challenging the treatment paradigm in metastatic renal cancer: Time to separate IMDC intermediate / poor risk groups?
2024 · J. McGrane, R. Frazer, et al. · Annals of Oncology
First-line Chemotherapy (FLC) Regimens in Older Adults (>65 years old) with Metastatic HER2-negative Breast Cancer (MBC): a Single-centre Experience of Tolerability and Efficacy
2019 · T. Wilson, C. Dyke, et al. · Clinical Oncology
Long-term remission of postmenopausal ovarian hyperandrogenism may occur following a period of gonadotropin-releasing hormone (GnRH) agonist therapy
2012 · Carly Lawrence, Claire Dyke, et al. · Endocrine Abstracts
Works count: 7
Citation count: 28
H-index: 3
I10-index: 1
Year
Topic
Type